Genome Engineering in Cyanobacteria: Where We Are and Where We Need To Go

被引:48
|
作者
Ramey, C. Josh [1 ]
Baron-Sola, Angel [1 ]
Aucoin, Hanna R. [1 ]
Boyle, Nanette R. [1 ]
机构
[1] Colorado Sch Mines, Chem & Biol Engn Dept, Golden, CO 80401 USA
来源
ACS SYNTHETIC BIOLOGY | 2015年 / 4卷 / 11期
关键词
RIBOSOME BINDING-SITES; STRAIN PCC 6803; GENE-EXPRESSION; SYNTHETIC BIOLOGY; SYNECHOCOCCUS SP; ESCHERICHIA-COLI; SIGMA FACTORS; HISTIDINE KINASES; HETEROCYST DIFFERENTIATION; BUTANOL-TOLERANCE;
D O I
10.1021/acssynbio.5b00043
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Genome engineering of cyanobacteria is a promising area of development in order to produce fuels, feedstocks, and value-added chemicals in a sustainable way. Unfortunately, the current state of genome engineering tools for cyanobacteria lags far behind those of model organisms such as Escherichia coli and Saccharomyces cerevisiae. In this review, we present the current state of synthetic biology tools for genome engineering efforts in the most widely used cyanobacteria strains and areas that need concerted research efforts to improve tool development. Cyanobacteria pose unique challenges to genome engineering efforts because their cellular biology differs significantly from other eubacteria; therefore, tools developed for other genera are not directly transferrable. Standardized parts, such as promoters and ribosome binding sites, which control gene expression, require characterization in cyanobacteria in order to have fully predictable results. The application of these tools to genome engineering efforts is also discussed; the ability to do genome-wide searching and to introduce multiple mutations simultaneously is an area that needs additional research in order to enable fast and efficient strain engineering.
引用
收藏
页码:1186 / 1196
页数:11
相关论文
共 50 条
  • [41] Vaccines against Tuberculosis: Where Are We and Where Do We Need to Go?
    Ottenhoff, Tom H. M.
    Kaufmann, Stefan H. E.
    PLOS PATHOGENS, 2012, 8 (05)
  • [42] A half century later: Where are we? Where do we need to go?
    Barraga, NC
    JOURNAL OF VISUAL IMPAIRMENT & BLINDNESS, 2004, 98 (10) : 581 - 583
  • [43] Syndesmotic Injuries: Where Are We Now? Where Do We Need To Go?
    Mediouni, Mohamed
    Schlatterer, Daniel R.
    Gardner, Michael
    JOURNAL OF FOOT & ANKLE SURGERY, 2017, 56 (05): : 1129 - 1129
  • [44] Advancing womanist identity development: Where we are and where we need to go
    Moradi, B
    COUNSELING PSYCHOLOGIST, 2005, 33 (02): : 225 - 253
  • [45] High-frequency oscillations - Where we are and where we need to go
    Engel, Jerome, Jr.
    da Silva, Fernando Lopes
    PROGRESS IN NEUROBIOLOGY, 2012, 98 (03) : 316 - 318
  • [46] Restorative care in nursing homes: Where we are and where we need to go
    Resnick, B
    Remsburg, R
    Zimmerman, S
    Gruber-Baldini, A
    Berkovitz, A
    GERONTOLOGIST, 2004, 44 : 287 - 287
  • [47] Oncology nursing certification: Where we are and where we need to go.
    Brown, Carlton
    Nicholson, Lori
    Ponto, Julie
    ONCOLOGY NURSING FORUM, 2007, 34 (02) : 526 - 527
  • [48] Teachers and science curriculum materials: where we are and where we need to go
    Davis, Elizabeth A.
    Janssen, Fred J. J. M.
    Van Driel, Jan H.
    STUDIES IN SCIENCE EDUCATION, 2016, 52 (02) : 127 - 160
  • [49] Multidisciplinary care for psoriatic disease Where we are and where we need to go
    Queiro, Ruben
    Coto, Pablo
    RHEUMATOLOGY, 2017, 56 (11) : 1829 - 1831
  • [50] California's oak woodlands: Where we have been, where we are, where we need to go
    Thomas, JW
    PROCEEDINGS OF A SYMPOSIUM ON OAK WOODLANDS: ECOLOGY, MANAGEMENT, AND URBAN INTERFACE ISSUES, 1997, : 3 - 9